Company profile
HAVN Life Sciences Inc.
OTC: HAVLF · Healthcare · Biotechnology
Canadian filerHQ Port Moody, BCReports USD
#996 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 17
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, Piotroski F · ↓ return on equity, market scale
Methodology →Revenue TTM
$451.3k
Rev growth YoY (TTM)
+843.3%
Net income (FY)
-$17.9M
Employees
6
as of 2026-08-30
Market cap
$2.6k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$220.4k276.5k CAD2022
Net income-$17.9M-22.4M CAD2022
Operating income-$7.8M-9.8M CAD2022
Total assets$3.2M4.1M CAD2022
Liabilities$718.0k918.5k CAD2022
Equity$2.5M3.1M CAD2022
Revenue trend
FY2020 – FY2022 · USD
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is HAVN Life Sciences Inc.’s revenue?
HAVN Life Sciences Inc. booked $220.4k in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -8117.8% net margin.
Peers · Healthcare
Regen BioPharma, Inc.35DBlueberries Medical Corp.32DFamily Office of America Inc.37DBrain Scientific Inc.——Anixa Biosciences, Inc.52DGlucoTrack, Inc.28DKey facts
CEOTim Moore
SectorHealthcare
IndustryBiotechnology
HeadquartersPort Moody, BC
ExchangeOTC: HAVLF
Employees6
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.